Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing  therapies for people with rare diseases, has produced positive top-line results from a second Phase 3 clinical trial of Firdapse. The drug is used for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS).     This clinical trial was conducted using a protocol agreed to by the FDA through the Special Protocol Assessment (SPA) process, and had two prospectively defined co-p...